Profound Medical Corp. (TSE:PRN) Senior Officer Thomas Michael Tamberrino Purchases 13,333 Shares

Profound Medical Corp. (TSE:PRN) Senior Officer Thomas Michael Tamberrino acquired 13,333 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was purchased at an average price of C$10.65 per share, for a total transaction of C$141,996.45.

Profound Medical Stock Performance

Shares of TSE:PRN traded down C$0.13 on Wednesday, reaching C$10.71. 2,275 shares of the company’s stock were exchanged, compared to its average volume of 7,405. The firm has a market capitalization of C$262.18 million, a price-to-earnings ratio of -6.53 and a beta of 0.81. Profound Medical Corp. has a fifty-two week low of C$9.55 and a fifty-two week high of C$15.75. The business’s 50-day moving average is C$10.82 and its two-hundred day moving average is C$11.60. The company has a quick ratio of 14.98, a current ratio of 8.61 and a debt-to-equity ratio of 16.95.

Analyst Upgrades and Downgrades

Separately, Raymond James upgraded Profound Medical to a “strong-buy” rating in a research note on Saturday, November 9th.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.